β-adrenergic receptor antagonists and fracture risk: a meta-analysis of selectivity, gender, and site-specific effects
Published 2013 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
β-adrenergic receptor antagonists and fracture risk: a meta-analysis of selectivity, gender, and site-specific effects
Authors
Keywords
β-adrenergic antagonists, Fracture, Osteoporosis
Journal
OSTEOPOROSIS INTERNATIONAL
Volume 25, Issue 1, Pages 121-129
Publisher
Springer Nature America, Inc
Online
2013-10-09
DOI
10.1007/s00198-013-2498-z
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- Targeting the osteoblast: approved and experimental anabolic agents for the treatment of osteoporosis
- (2014) Konstantinos Toulis et al. Hormones-International Journal of Endocrinology and Metabolism
- β1 selectivity of β-blockers and reduced risk of fractures in elderly hypertension patients
- (2012) Hong Ji Song et al. BONE
- Association between beta-blockers and fracture risk: A Bayesian meta-analysis
- (2012) Shuman Yang et al. BONE
- The Relationship Among Hypertension, Antihypertensive Medications, and Osteoporosis: A Narrative Review
- (2012) Katarina Ilić et al. CALCIFIED TISSUE INTERNATIONAL
- Deletion of β-adrenergic receptor 1, 2, or both leads to different bone phenotypes and response to mechanical stimulation
- (2012) Dominique D Pierroz et al. JOURNAL OF BONE AND MINERAL RESEARCH
- Heart Failure Is a Clinically and Densitometrically Independent Risk Factor for Osteoporotic Fractures: Population-Based Cohort Study of 45,509 Subjects
- (2012) Sumit R. Majumdar et al. JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM
- Anabolic action of parathyroid hormone regulated by the 2-adrenergic receptor
- (2012) R. Hanyu et al. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA
- Acid suppressants and hip fracture: Duplicate publication bias?
- (2011) Marloes Bazelier et al. BONE
- Low dose of propranolol down-modulates bone resorption by inhibiting inflammation and osteoclast differentiation
- (2011) WF Rodrigues et al. BRITISH JOURNAL OF PHARMACOLOGY
- β2-Adrenergic Receptor Signaling in Osteoblasts Contributes to the Catabolic Effect of Glucocorticoids on Bone
- (2011) Yun Ma et al. ENDOCRINOLOGY
- Risk of fractures in older adults using antihypertensive medications
- (2011) Daniel H Solomon et al. JOURNAL OF BONE AND MINERAL RESEARCH
- Sympathetic control of bone mass regulated by osteopontin
- (2011) M. Nagao et al. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA
- Association between beta-blocker use and fracture risk: The Dubbo Osteoporosis Epidemiology Study
- (2010) Shuman Yang et al. BONE
- Continuous Treatment with a Low-Dose β-Agonist Reduces Bone Mass by Increasing Bone Resorption Without Suppressing Bone Formation
- (2010) Hisataka Kondo et al. CALCIFIED TISSUE INTERNATIONAL
- Bone mineral density variation in men is influenced by sex-specific and non sex-specific quantitative trait loci
- (2009) Munro Peacock et al. BONE
- Race and sex differences in bone mineral density and geometry at the femur
- (2009) M. Peacock et al. BONE
- Regulation of bone remodeling by the central and peripheral nervous system
- (2008) Florent Elefteriou ARCHIVES OF BIOCHEMISTRY AND BIOPHYSICS
- β2-Adrenoreceptor ligands regulate osteoclast differentiation in vitro by direct and indirect mechanisms
- (2008) Sarah J. Aitken et al. ARCHIVES OF BIOCHEMISTRY AND BIOPHYSICS
- Molecular bases of the sympathetic regulation of bone mass
- (2008) Shu Takeda et al. BONE
- Low dose beta-blocker prevents ovariectomy-induced bone loss in rats without affecting heart functions
- (2008) N. Bonnet et al. JOURNAL OF CELLULAR PHYSIOLOGY
Find Funding. Review Successful Grants.
Explore over 25,000 new funding opportunities and over 6,000,000 successful grants.
ExplorePublish scientific posters with Peeref
Peeref publishes scientific posters from all research disciplines. Our Diamond Open Access policy means free access to content and no publication fees for authors.
Learn More